Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Gains from Sales and Divestitures (2022 - 2025)

Biote has reported Gains from Sales and Divestitures over the past 4 years, most recently at $24039.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $24039.0 for Q4 2025, down 94.6% from a year ago — trailing twelve months through Dec 2025 was $24039.0 (down 94.6% YoY), and the annual figure for FY2025 was $24039.0, down 94.6%.
  • Gains from Sales and Divestitures for Q4 2025 was $24039.0 at Biote, roughly flat from $24039.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for BTMD hit a ceiling of $2.1 million in Q4 2022 and a floor of $24039.0 in Q2 2025.
  • Median Gains from Sales and Divestitures over the past 4 years was $444783.0 (2024), compared with a mean of $596666.1.
  • Biggest five-year swings in Gains from Sales and Divestitures: grew 25.68% in 2023 and later tumbled 94.6% in 2025.
  • Biote's Gains from Sales and Divestitures stood at $2.1 million in 2022, then crashed by 39.11% to $1.3 million in 2023, then plummeted by 64.43% to $444783.0 in 2024, then tumbled by 94.6% to $24039.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $24039.0 (Q4 2025), $24039.0 (Q3 2025), and $24039.0 (Q2 2025) per Business Quant data.